Acumen, JCR partner to enhance Alzheimer’s therapy delivery
The partnership combines Acumen's expertise in amyloid beta oligomer-selective antibodies with JCR's blood-brain barrier-penetrating technology, to improve AD treatment delivery.
A leading resource for the Pharmaceutical industry since 2002
The partnership combines Acumen's expertise in amyloid beta oligomer-selective antibodies with JCR's blood-brain barrier-penetrating technology, to improve AD treatment delivery.